Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Sep;23(5):611-612.
doi: 10.1007/s43678-021-00154-3. Epub 2021 Jul 19.

Is inhaled budesonide an effective treatment for patients with mild early symptoms of COVID-19?

Hashim Kareemi  1 , Hans Rosenberg  2 , Krishan Yadav  2   3
Affiliations
Editorial

Is inhaled budesonide an effective treatment for patients with mild early symptoms of COVID-19?

Hashim Kareemi et al. CJEM. 2021 Sep.
No abstract available

Keywords: Budesonide; COVID-19; RCT; Steroids.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Comment on

  • Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
    Ramakrishnan S, Nicolau DV Jr, Langford B, Mahdi M, Jeffers H, Mwasuku C, Krassowska K, Fox R, Binnian I, Glover V, Bright S, Butler C, Cane JL, Halner A, Matthews PC, Donnelly LE, Simpson JL, Baker JR, Fadai NT, Peterson S, Bengtsson T, Barnes PJ, Russell REK, Bafadhel M. Ramakrishnan S, et al. Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9. Lancet Respir Med. 2021. PMID: 33844996 Free PMC article. Clinical Trial.

References

    1. YuBafadhel LM, Dorward J. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. MedRxiv. 2021. 10.1101/2021.04.10.21254672.